5 Key Takeaways

• 1

  Corneal crosslinking is a key intervention for progressive keratoconus and post-LASIK ectasia, approved by the FDA since 2013.

• 2

  The epi-on procedure, recently approved by the FDA, offers a non-invasive option but lacks payer coverage due to its experimental status.

• 3

  Rising costs of the riboflavin drug Photrexa and inconsistent reimbursement create financial challenges for practices offering crosslinking.

• 4

  Despite most payers covering the epi-off procedure, it remains a Category III CPT code, complicating reimbursement and documentation.

• 5

  Without improved payer support, access to corneal crosslinking may decline, potentially shifting care to higher-cost academic centers.